Please note that Systems Microbiology does not consider descriptive studies that are solely based on amplicon (e.g., 16S rRNA) profiles, unless they are accompanied by a clear hypothesis and experimentation, and provide insight into the microbiological system or process being studied.
Some strains of live microorganisms confer health benefits (probiotics) or therapeutic properties (LBP; live biotherapeutic products) when present or administered at adequate levels.
Until now the gold-standard for measuring potency of live microbial products has been colony-forming units (CFU) enumeration. However, gaps between current analysis methodology and the need for reliable strain-level viability enumeration have been reported. To ensure the presence of adequate levels of viable beneficial microorganisms, industries, researchers, and regulatory agencies look to emerging technologies for solutions to test and document product quality, maintain consumer confidence, and enhance understanding of live microorganism systems.
Recently, there has been growing interest surrounding emerging technologies being applied to live microorganism analysis, and this has initiated a conversation on potential roles for such technologies in live microorganism industries. This research topic is intended to continue this conversation, and provide results and insights for further studies within this area.
The research topic invites manuscript submissions of studies exploring how next-generation technologies can be used to obtain reliable, high throughput, affordable viability enumeration of live organisms. Non-commercially oriented manuscripts that focus on the use of emerging technologies will be considered. For example, manuscripts that:
• Describe and demonstrate new and/or novel technological approaches.
• Demonstrate practical application(s)/provides solutions for use in research and development, manufacturing, and/or quality control.
• Address strain-selective enumeration.
• Evaluate the compendial potential of new technology, i.e., verifying method suitability under the actual condition of use.
• Compare emerging technology(ies) to classical method(s) or to other next-generation technologies.
• Show how emerging technologies can be used to conceptualize a design and/or product rationale.
• Make use of case studies/commentaries/opinions to demonstrate and explain challenges encountered when adopting or transitioning to emerging technologies.
Jean Schoeni is employed by Eurofins, a contract laboratory that provides services to live microorganism industries, including enumeration. As Owner and Principal of JeanLSchoeni, LLC, they have consulted with probiotic ingredient manufacturers.
Christina Vegge is employed by Probi, an ingredient manufacturer of probiotics.
Marco Pane is employed by Probiotical, an ingredient manufacturer of probiotics.
Hanan Shehata is employed by Purity-IQ, a company specializing in product authentication.
Please note that Systems Microbiology does not consider descriptive studies that are solely based on amplicon (e.g., 16S rRNA) profiles, unless they are accompanied by a clear hypothesis and experimentation, and provide insight into the microbiological system or process being studied.
Some strains of live microorganisms confer health benefits (probiotics) or therapeutic properties (LBP; live biotherapeutic products) when present or administered at adequate levels.
Until now the gold-standard for measuring potency of live microbial products has been colony-forming units (CFU) enumeration. However, gaps between current analysis methodology and the need for reliable strain-level viability enumeration have been reported. To ensure the presence of adequate levels of viable beneficial microorganisms, industries, researchers, and regulatory agencies look to emerging technologies for solutions to test and document product quality, maintain consumer confidence, and enhance understanding of live microorganism systems.
Recently, there has been growing interest surrounding emerging technologies being applied to live microorganism analysis, and this has initiated a conversation on potential roles for such technologies in live microorganism industries. This research topic is intended to continue this conversation, and provide results and insights for further studies within this area.
The research topic invites manuscript submissions of studies exploring how next-generation technologies can be used to obtain reliable, high throughput, affordable viability enumeration of live organisms. Non-commercially oriented manuscripts that focus on the use of emerging technologies will be considered. For example, manuscripts that:
• Describe and demonstrate new and/or novel technological approaches.
• Demonstrate practical application(s)/provides solutions for use in research and development, manufacturing, and/or quality control.
• Address strain-selective enumeration.
• Evaluate the compendial potential of new technology, i.e., verifying method suitability under the actual condition of use.
• Compare emerging technology(ies) to classical method(s) or to other next-generation technologies.
• Show how emerging technologies can be used to conceptualize a design and/or product rationale.
• Make use of case studies/commentaries/opinions to demonstrate and explain challenges encountered when adopting or transitioning to emerging technologies.
Jean Schoeni is employed by Eurofins, a contract laboratory that provides services to live microorganism industries, including enumeration. As Owner and Principal of JeanLSchoeni, LLC, they have consulted with probiotic ingredient manufacturers.
Christina Vegge is employed by Probi, an ingredient manufacturer of probiotics.
Marco Pane is employed by Probiotical, an ingredient manufacturer of probiotics.
Hanan Shehata is employed by Purity-IQ, a company specializing in product authentication.
